{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-258629","form_type":"8-K","ticker":"SVRA","cik":"0001160308","company_name":"Savara Inc","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.908266+00:00","generated_at":"2026-05-17T01:14:42.393767+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share","bullets":["23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.","Underwriters granted 30-day option to purchase up to an additional 4.6M shares.","Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.","Offering expected to close October 31, 2025, subject to customary conditions.","Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-258629","json":"https://secwatch.observer/filing/0001193125-25-258629.json","markdown":"https://secwatch.observer/filing/0001193125-25-258629.md","text":"https://secwatch.observer/filing/0001193125-25-258629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/0001193125-25-258629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1160308/000119312525258629/d62228d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:14:42.393767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}